ZyVersa Engages George Clinical for Phase 2a Trial

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing drugs for renal and inflammatory diseases, has selected George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin 1Q24.
 
George Clinical, a global CRO headquartered in Sydney, Australia, provides clinical trial services to pharmaceutical, medical device, and diagnostic customers for all trial phases, registration, and post-marketing trials. 
 
“Initiation of the Phase 2a trial in patients with DKD marks a major milestone in the development of Cholesterol Efflux MediatorTM VAR 200 and for ZyVersa. It is the first clinical trial for VAR 200 and will help establish its effectiveness and safety in renal patients, and it will provide valuable insights to guide development for other planned renal indications (focal segmental glomerulosclerosis and Alport syndrome),” said Stephen C. Glover, ZyVersa’s Co-founder, Chief Executive Officer, and Chairman. “We are pleased to partner with George Clinical to manage this important study.”
 
“Collaborating with ZyVersa Therapeutics on this trial shows not only our passion for kidney research but also the commitment to provide the necessary clinical research around innovative treatments that could help patients with unmet medical needs,” said George Clinical Chief Medical Officer Maria Ali.